DK3774795T3 - 4-(1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]-pyridiner til anvendelse ved behandling af leukæmier, lymfomer og solide tumorer - Google Patents

4-(1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]-pyridiner til anvendelse ved behandling af leukæmier, lymfomer og solide tumorer Download PDF

Info

Publication number
DK3774795T3
DK3774795T3 DK19715027.9T DK19715027T DK3774795T3 DK 3774795 T3 DK3774795 T3 DK 3774795T3 DK 19715027 T DK19715027 T DK 19715027T DK 3774795 T3 DK3774795 T3 DK 3774795T3
Authority
DK
Denmark
Prior art keywords
leuchemia
pyridines
lymphomas
pyrrolo
imidazol
Prior art date
Application number
DK19715027.9T
Other languages
English (en)
Inventor
Vitezslav Bryja
Pavlina Janovska
Michaela Gregorova
Vaclav Nemec
Prashant Khirsariya
Kamil Paruch
Original Assignee
Univ Masarykova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Masarykova filed Critical Univ Masarykova
Application granted granted Critical
Publication of DK3774795T3 publication Critical patent/DK3774795T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK19715027.9T 2018-03-29 2019-03-26 4-(1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]-pyridiner til anvendelse ved behandling af leukæmier, lymfomer og solide tumorer DK3774795T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18164938 2018-03-29
PCT/EP2019/057595 WO2019185631A1 (en) 2018-03-29 2019-03-26 4—(1h— imidazol— 5— yl) -1h-pyrrolo [2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors

Publications (1)

Publication Number Publication Date
DK3774795T3 true DK3774795T3 (da) 2022-06-27

Family

ID=61837684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19715027.9T DK3774795T3 (da) 2018-03-29 2019-03-26 4-(1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]-pyridiner til anvendelse ved behandling af leukæmier, lymfomer og solide tumorer

Country Status (13)

Country Link
US (1) US11498920B2 (da)
EP (1) EP3774795B1 (da)
JP (1) JP7008967B2 (da)
KR (1) KR102465111B1 (da)
CN (1) CN111936496B (da)
AU (1) AU2019246220B2 (da)
CA (1) CA3085967C (da)
DK (1) DK3774795T3 (da)
ES (1) ES2918448T3 (da)
PL (1) PL3774795T3 (da)
PT (1) PT3774795T (da)
SI (1) SI3774795T1 (da)
WO (1) WO2019185631A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795160B2 (en) 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
JP2023503988A (ja) * 2019-11-29 2023-02-01 ファシオ インテレクチュアル プロパティ ビー．ヴイ． Ｄｕｘ４発現に関連する疾患を処置するための新たな化合物
CA3208490A1 (en) 2021-02-24 2022-09-01 Aleksandrs Zavoronkovs Analogs for the treatment of disease
CN114315729B (zh) * 2021-12-09 2024-01-26 大连理工大学 1-苄基-2，4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085269A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
CZ2012538A3 (cs) * 2012-08-08 2014-02-19 Masarykova Univerzita Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie
WO2014100533A1 (en) * 2012-12-21 2014-06-26 Bristol-Myers Squibb Company NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS
EA037112B1 (ru) 2015-03-02 2021-02-08 Ригель Фармасьютикалс, Инк. Ингибиторы tgf-

Also Published As

Publication number Publication date
US20210040086A1 (en) 2021-02-11
JP7008967B2 (ja) 2022-01-25
KR20200116137A (ko) 2020-10-08
AU2019246220A1 (en) 2020-07-09
CN111936496B (zh) 2023-12-29
CA3085967C (en) 2022-10-18
CA3085967A1 (en) 2019-10-03
CN111936496A (zh) 2020-11-13
WO2019185631A1 (en) 2019-10-03
PT3774795T (pt) 2022-07-20
US11498920B2 (en) 2022-11-15
ES2918448T3 (es) 2022-07-15
KR102465111B1 (ko) 2022-11-09
EP3774795A1 (en) 2021-02-17
EP3774795B1 (en) 2022-03-16
SI3774795T1 (sl) 2022-07-29
JP2021517157A (ja) 2021-07-15
PL3774795T3 (pl) 2022-07-04
AU2019246220B2 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
IL288104A (en) Heterocyclic compounds, preparation methods and uses thereof
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
LT4303583T (lt) Csf1r inhibitoriai, skirti panaudoti gydant tenosinovinius gigantinių ląstelių navikus
DK3464285T3 (da) Fremgangsmåde til fremstilling af n-(5-(3-(7-(3-fluorphenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamid
IL252839B (en) Btk inhibitor (r,e)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl )-1h-pyrazolo [3, 4-d]-pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile for use in the treatment of pemphigus
DK3445451T3 (da) Sammensætninger og fremgangsmåder til behandling af lysosomale lagringssygdomme og sygdomme kendetegnet ved lysosomal dysfunktion
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
DK3774795T3 (da) 4-(1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]-pyridiner til anvendelse ved behandling af leukæmier, lymfomer og solide tumorer
SI3359541T1 (sl) N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe
EP3319936A4 (en) BRIDGE LINKER FOR CONJUGATING CELL BINDING MOLECULES
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
DK3500571T3 (da) Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf
EP3326413A4 (en) USER LEVELS FOR CELLULAR ARCHITECTURE OF THE FIFTH GENERATION
DK3481827T3 (da) Imidazo[1,2-a]pyridinderivater, fremgangsmåder til fremstilling og anvendelse deraf
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
DK3697784T5 (da) Imidazo[4,5-b]pyridinforbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske forstyrrelser
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
HUE051448T2 (hu) Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
IL285792A (en) Composition and container, kit, method of use
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3556383T3 (da) Plasminogen til anvendelse ved behandling af diabetes
DK4076461T3 (da) Lumateperon til brug ved behandling af skizofreni
DK3797107T3 (da) Heterokondenserede pyridonforbindelser og anvendelse deraf som idh- hæmmere
IL263804A (en) Wnt inhibitors for use in the treatment of fibrosis